Literature DB >> 21970563

Neuromuscular blockers and ARDS: thou shalt not breathe, move, or die!

Balaji Yegneswaran1, Raghavan Murugan.   

Abstract

Entities:  

Year:  2011        PMID： 21970563      PMCID： PMC3334776          DOI： 10.1186/cc10470

Source DB:  PubMed          Journal:  Crit Care        ISSN： 1364-8535            Impact factor:   9.097


× No keyword cloud information.
  13 in total

1.  Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient.

Authors:  Michael J Murray; Jay Cowen; Heidi DeBlock; Brian Erstad; Anthony W Gray; Ann N Tescher; William T McGee; Richard C Prielipp; Greg Susla; Judith Jacobi; Stanley A Nasraway; Philip D Lumb
Journal:  Crit Care Med       Date:  2002-01       Impact factor: 7.598

2.  Intensive care unit drug use and subsequent quality of life in acute lung injury patients.

Authors:  B J Nelson; C R Weinert; C L Bury; W A Marinelli; C R Gross
Journal:  Crit Care Med       Date:  2000-11       Impact factor: 7.598

Review 3.  Severe hypoxemic respiratory failure: part 2--nonventilatory strategies.

Authors:  Suhail Raoof; Keith Goulet; Adebayo Esan; Dean R Hess; Curtis N Sessler
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

4.  Paresis acquired in the intensive care unit: a prospective multicenter study.

Authors:  Bernard De Jonghe; Tarek Sharshar; Jean-Pascal Lefaucheur; François-Jérome Authier; Isabelle Durand-Zaleski; Mohamed Boussarsar; Charles Cerf; Estelle Renaud; Francine Mesrati; Jean Carlet; Jean-Claude Raphaël; Hervé Outin; Sylvie Bastuji-Garin
Journal:  JAMA       Date:  2002-12-11       Impact factor: 56.272

5.  Incidence and mortality after acute respiratory failure and acute respiratory distress syndrome in Sweden, Denmark, and Iceland. The ARF Study Group.

Authors:  O R Luhr; K Antonsen; M Karlsson; S Aardal; A Thorsteinsson; C G Frostell; J Bonde
Journal:  Am J Respir Crit Care Med       Date:  1999-06       Impact factor: 21.405

6.  Critical illness polyneuropathy: risk factors and clinical consequences. A cohort study in septic patients.

Authors:  J Garnacho-Montero; J Madrazo-Osuna; J L García-Garmendia; C Ortiz-Leyba; F J Jiménez-Jiménez; A Barrero-Almodóvar; M C Garnacho-Montero; M R Moyano-Del-Estad
Journal:  Intensive Care Med       Date:  2001-08       Impact factor: 17.440

7.  Neuromuscular blockers in early acute respiratory distress syndrome.

Authors:  Laurent Papazian; Jean-Marie Forel; Arnaud Gacouin; Christine Penot-Ragon; Gilles Perrin; Anderson Loundou; Samir Jaber; Jean-Michel Arnal; Didier Perez; Jean-Marie Seghboyan; Jean-Michel Constantin; Pierre Courant; Jean-Yves Lefrant; Claude Guérin; Gwenaël Prat; Sophie Morange; Antoine Roch
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

Review 8.  The design of randomized clinical trials in critically ill patients.

Authors:  Paul C Hébert; Deborah J Cook; George Wells; John Marshall
Journal:  Chest       Date:  2002-04       Impact factor: 9.410

9.  Incidence and outcomes of acute lung injury.

Authors:  Gordon D Rubenfeld; Ellen Caldwell; Eve Peabody; Jim Weaver; Diane P Martin; Margaret Neff; Eric J Stern; Leonard D Hudson
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

10.  Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome.

Authors:  Marc Gainnier; Antoine Roch; Jean-Marie Forel; Xavier Thirion; Jean-Michel Arnal; Stéphane Donati; Laurent Papazian
Journal:  Crit Care Med       Date:  2004-01       Impact factor: 7.598
View more
  2 in total

Review 1.  Managing Persistent Hypoxemia: what is new?

Authors:  Jesús Villar; Carlos Ferrando; Robert M Kacmarek
Journal:  F1000Res       Date:  2017-11-13

Review 2.  Unsuccessful and Successful Clinical Trials in Acute Respiratory Distress Syndrome: Addressing Physiology-Based Gaps.

Authors:  Jesús Villar; Carlos Ferrando; Gerardo Tusman; Lorenzo Berra; Pedro Rodríguez-Suárez; Fernando Suárez-Sipmann
Journal:  Front Physiol       Date:  2021-11-30       Impact factor: 4.566
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.